Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
about
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine modelRifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TBTMC207: the first compound of a new class of potent anti-tuberculosis drugsWeekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsHeterogeneity in tuberculosis pathology, microenvironments and therapeutic responsesImpact of vitamin D on infectious diseaseA medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosisMycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferationImmune markers measured before treatment predict outcome of intensive phase tuberculosis therapyBuilding clinical trials capacity for tuberculosis drugs in high-burden countriesEffect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysisPotential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infectionA bispecific antibody based assay shows potential for detecting tuberculosis in resource constrained laboratory settingsEffect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosisAdvances in the diagnosis and treatment of tuberculosis.Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis.Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.Impact of DOTS expansion on tuberculosis related outcomes and costs in HaitiWhy is long-term therapy required to cure tuberculosis?A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis.Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis.Does directly observed therapy (DOT) reduce drug resistant tuberculosis?Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tubercuCost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe association between symptoms and microbiologically defined response to tuberculosis treatment.Priorities for screening and treatment of latent tuberculosis infection in the United StatesThe burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational studyVitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis.Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotypeHigh-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trialCurrent approaches to tuberculosis in the United States.Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.Analysis of antibody responses to Mycobacterium leprae phenolic glycolipid I, lipoarabinomannan, and recombinant proteins to define disease subtype-specific antigenic profiles in leprosy.Current concepts in the management of tuberculosis
P2860
Q21144660-24665747-5CEB-4232-A75C-0B6A9A6E40D6Q24201325-6A723622-0EA8-4442-B011-03DB33AC514BQ24632091-6497E04E-9533-4E5D-A04C-46531760E5D8Q24650581-12456F3B-F5B9-4AF7-92EA-E68829CE64B3Q26823503-66670DA5-377D-4D16-A9B2-E0D40F385462Q27000724-8681101C-A0F7-4E24-80DC-6175250BD32AQ27004482-08639E70-E2E8-4CF6-AE76-AB8D7A02960FQ28385840-3DF9A80B-C3FD-4DF5-A9A5-A8EB63B16B57Q28396491-89774864-B722-494C-BF2E-394BF7461C8FQ28469348-2C04F440-9BA8-49ED-9750-A7FF6C26A71BQ28476120-770A4E45-01E4-44F1-BF08-F81BB2FEA5C1Q28479103-6F48DD97-7089-48E0-AB9C-25B0A2F704CAQ28481078-0AA4B493-1B09-4CC9-8CAA-4346A2C739D6Q28729980-D29BD70C-3DA5-4DEA-9239-62D4C96E242FQ30353049-828A0EE4-3F64-4D08-A77D-BBF1A158D37FQ30414897-2995F47B-0FE2-4A00-9AE2-09DFB02ED319Q33165650-FBA82C30-EEDB-4A25-8670-FF9FFDA240A5Q33254073-7E4D9233-E0F0-45AC-8A32-C4B4B872036CQ33280142-37E9A684-901C-45E6-847A-EC63E34B19B8Q33379045-D225EAFB-658F-4FC1-AC75-E17C9022D202Q33503248-F82ACBAD-6864-4ED1-8C48-80865EC38C75Q33590272-DEE34464-6D37-47A9-890D-19E4301F4336Q33627062-DC15BA94-4E89-4AD4-A3D9-CAD68020B349Q33788435-B2C2F8FE-2CC9-4DB7-9012-54360A56B9D7Q33798120-A4456EF0-0B87-47AD-A748-FD3738AD2DB0Q33804506-5A4CB3DA-39AD-47C7-ABBC-F13D02B5E446Q33837706-05B24A01-E794-4AB9-A909-E4D3DA9E8286Q33872018-7ADECD5C-B001-41A6-B9DB-5F879E8A5FDEQ33895875-ECA29F2D-584D-4139-B20C-3193508AF8EBQ33909586-8C7A8683-5454-4A64-B602-20CD0B95FD88Q34065366-E07B8FEF-1ED1-4624-9E50-1FB28507ECE3Q34077125-8624F49B-F148-4C24-B985-2A8F7BE1C1BDQ34125133-3F985573-40CF-4A1C-9653-580B280F62D4Q34158057-C8500D86-E13C-48D9-84AF-5C6AE3D07783Q34279727-AABD386C-8543-4579-B8F9-0AB1C0FEE7C6Q34433240-6FB345C9-D4F0-4965-9214-3E11D986A587Q34519945-78534E85-10C6-476F-A870-AD74B732CD0BQ34718431-B724BA0F-EF31-46B4-B107-20579CD59D1EQ34738690-B168105E-ADE5-43EA-9563-54F42A28D628Q34748542-15F767D1-744D-428B-96A2-B57604C37C97
P2860
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@en
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@nl
type
label
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@en
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@nl
prefLabel
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@en
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@nl
P2093
P1433
P1476
Rifapentine and isoniazid once ...... : a randomised clinical trial.
@en
P2093
Andrew Vernon
Antonino Cantazaro
Beverly Metchock
C Robert Horsburgh
Christopher Lahart
Constance Pachucki
Debra Benator
Fred Gordin
James Horton
P304
P356
10.1016/S0140-6736(02)09742-8
P407
P577
2002-08-01T00:00:00Z